Akut Radyasyon Sendromunda Analjezi
Özet
Akut Radyasyon Sendromu (ARS) sonrasında gelişen doku ve organ hasarları, hastaların neredeyse tamamında analjezik tedaviyi zorunlu kılmaktadır. Bu süreçte tedavi, ARS'nin fazlarına ve kutanöz, hematopoetik, gastrointestinal gibi alt sendromlara göre bireyselleştirilmelidir. İlk basamakta ucuz ve minimal etkileşimli asetaminofen tercih edilirken, opioidler ve nörovasküler hasara yönelik gabapentinoidler yan etki ve bağımlılık riskleri gözetilerek multimodal yaklaşımla kombine edilmelidir. Özellikle cilt lezyonlarında ağrı kontrolü ve prosedürel analjezi hayati önem taşır. Gastrointestinal harabiyet durumunda ise oral emilim bozuklukları nedeniyle tedavi protokolü opioid rotasyonu ve adjuvan ilaçlarla desteklenmelidir. Sonuç olarak, ARS hastalarında başarılı bir analjezi, ancak sistemik organ etkilenimleri ile hastanın psikolojik durumunun bir arada değerlendirildiği bütüncül bir bakımla mümkündür.
Acute Radiation Syndrome (ARS) induces extensive tissue and organ damage, rendering analgesic treatment essential for nearly all affected patients. The management must be individualized based on the specific phases of ARS and its subsyndromes, including cutaneous, hematopoietic, and gastrointestinal manifestations. Acetaminophen is preferred as an initial agent due to its low cost and minimal drug interactions, while opioids and gabapentinoids, targeted at neurovascular damage, should be integrated into a multimodal approach while carefully monitoring addiction and side effect risks. Pain control and procedural analgesia are particularly critical in managing cutaneous lesions. In the presence of gastrointestinal damage, compromised oral absorption necessitates supporting the protocol with opioid rotation and adjuvant medications. Ultimately, successful analgesia in ARS patients can only be achieved through holistic care that comprehensively addresses both systemic organ involvement and the patient's psychological status.
Referanslar
DiCarlo AL, Bandremer AC, Hollingsworth BA, et al. Cutaneous radiation injuries: Models, assessment and treatments. Radiation research. 2020;194(3):315-44.
Kishi HS. Effects of the "Special Bomb": Recollections of A Neurosurgeon in Hiroshima, August 8-15, 1945. Neurosurgery. 2000;47(2):441-5;445-6.
Adams TG, Yeddanapudi N, Clay M, et al. Modeling Cutaneous Radiation Injury from Fallout. Disaster Med Public Health Prep. Cambridge University Press; 2019;13:463–9.
Barss NM, Weitz RL. Reconstruction of external dose from beta radiation sources of nuclear weapon origin. Health Phys. 2006;91:379–89.
Jones T. Planning Guidance for Response to a Nuclear Detonation. 2010.
Jacobson LK, Johnson MB, Dedhia RD, et al. Impaired wound healing after radiation therapy: A systematic review of pathogenesis and treatment. JPRAS Open. 2017;13:92–105.
Balter S, Hopewell JW, Miller DL, et al. Fluoroscopically guided interventional procedures: a review of radiation effects on patients’ skin and hair. Radiology. 2010;254(2):326-41.
İnce S. Acute Local Radiation Injury and Treatment Methods. Nucl Med Semin. 2017;3:201–6.
France CP, Ahern GP, Averick S, et al. Countermeasures for Preventing and Treating Opioid Overdose. Clin Pharmacol Ther Clin Pharmacol Ther. 2021;109:578–90.
Dhillon S. Tramadol/Paracetamol Fixed-Dose Combination. Clinical Drug Investigation. 2010;30(10):711-38.
Barakat A. Revisiting Tramadol: A Multi-Modal Agent for Pain Management. CNS Drugs. 2019;33(5):481–501.
Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361:1963–71.
Goodman CW, Brett AS. Gabapentinoids for Pain: Potential Unintended Consequences. Am Fam Physician. 2019;100:672–5.
Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. JAMA Intern Med. 2019;179:695–701.
Aaseth J, Nurchi VM, Andersen O. Medical Therapy of Patients Contaminated with Radioactive Cesium or Iodine. Biomolecules. 2019;9:856.
Iskandar L, Rojo L, Di Silvio L, et al. The effect of chelation of sodium alginate with osteogenic ions, calcium, zinc, and strontium. J Biomater Appl. 2019;34:573–84.
Nishimura Y, Kim HS, Ikota N, et al. Radioprotective effect of chitosan in sub-lethally X-ray irradiated mice. J Radiat Res. 2003;44:53–8.
Fukuda S. Chelating agents used for plutonium and uranium removal in radiation emergency medicine. Curr Med Chem. 2005;12:2765–70.
Guilmette RA, Muggenburg BA. Reducing the radiation dose from inhaled americium-241 using continuously administered DTPA therapy. Int J Radiat Biol Relat Stud Phys Chem Med. 1988;53:261–71.
Boland JW, Pockley AG. Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol. 2018;175:2726–36.
Cruz-Lebrón A, Johnson R, Mazahery C, et al. Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity. Gut Microbes. 2021;13:1.
Ninković J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 2013;45:9–24.
Plein LM, Rittner HL. Opioids and the immune system - friend or foe. Br J Pharmacol. 2018;175:2717–25.
Boland JW, Foulds GA, Ahmedzai SH, et al. A preliminary evaluation of the effects of opioids on innate and adaptive human in vitro immune function. BMJ Support Palliat Care. 2014;4:357–67.
Guskova AK. Medical Characteristics of Different Types of Radiation Accidents. In: Medical management of radiation accidents. 2nd edition. Editors: Gusev IA, Guskova AK, Mettler FA. CRC Press, New York, USA. 2001;15-22.
Goans RE. The Clinical Care of Victims. In: The Medical Basis for Radiation-Accident Preparedness: Editors: Ricks RC, Berger ME, O’Hara FMJ. CRC Press, New York, USA. 2002;11-22.
MacVittie TJ, Farese AM, Parker GA, et al. The gastrointestinal subsyndrome of the acute radiation syndrome in rhesus macaques: A systematic review of the lethal dose-response relationship with and without medical management. Health Phys. 2019;116:305–38.
